Working… Menu

Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01727336
Recruitment Status : Terminated (The study was terminated by the sponsor following unblinding of the Progression Free Survival endpoint.)
First Posted : November 16, 2012
Results First Posted : May 24, 2021
Last Update Posted : September 23, 2021
Information provided by (Responsible Party):
Acceleron Pharma Inc.

Information on FDAAA 801 Violations
More Information: Notices of Noncompliance [FDA]
Table of FDAAA 801 Violation Notices
Available on Issued by FDA Study Record Submitted Notice Type FDAAA 801 Notice
April 29, 2021 April 27, 2021 January 9, 2019 Violation Identified by FDA Failure to Submit. The entry for this clinical trial was not complete at the time of submission, as required by law. This may or may not have any bearing on the accuracy of the information in the entry.